Morgenstern Alfred, Bruchertseifer Frank, Apostolidis Christos
European Commission, Joint Research Centre, Institute for Transuranium Elements, 76125 Karlsruhe, Germany.
Curr Radiopharm. 2012 Jul;5(3):221-7. doi: 10.2174/1874471011205030221.
The alpha emitters (225)Ac and (213)Bi are promising therapeutic radionuclides for application in targeted alpha therapy of cancer and infectious diseases. Both alpha emitters are available with high specific activity from established radionuclide generators. Their favourable chemical and physical properties have led to the conduction of a large number of preclinical studies and several clinical trials, demonstrating the feasibility, safety and therapeutic efficacy of targeted alpha therapy with (225)Ac and (213)Bi. This review describes methods for the production of (225)Ac and (213)Bi and gives an overview of (225)Ac/(213)Bi radionuclide generator systems. Selected preclinical studies are highlighted and the current clinical experience with (225)Ac and (213)Bi is summarized.
α发射体（225）锕和（213）铋是很有前景的治疗性放射性核素，可用于癌症和传染病的靶向α治疗。这两种α发射体都可以从成熟的放射性核素发生器中获得高比活度产品。它们良好的化学和物理性质促使人们开展了大量临床前研究和多项临床试验，证明了使用（225）锕和（213）铋进行靶向α治疗的可行性、安全性和治疗效果。本综述描述了（225）锕和（213）铋的生产方法，并概述了（225）锕/（213）铋放射性核素发生器系统。重点介绍了选定的临床前研究，并总结了目前使用（225）锕和（213）铋的临床经验。
